Publications
Detailed Information
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Gadgeel, Shirish | - |
dc.contributor.author | Gettinger, Scott N. | - |
dc.contributor.author | Riely, Gregory J. | - |
dc.contributor.author | Oxnard, Geoffrey R. | - |
dc.contributor.author | Mekhail, Tarek | - |
dc.contributor.author | Schmid, Peter | - |
dc.contributor.author | Dowlati, Afshin | - |
dc.contributor.author | Heist, Rebecca S. | - |
dc.contributor.author | Wozniak, Antoinette J. | - |
dc.contributor.author | Singh, Jatinder | - |
dc.contributor.author | Cha, Edward | - |
dc.contributor.author | Spahn, Jessica | - |
dc.contributor.author | Ou, Sai-Hong Ignatius | - |
dc.date.accessioned | 2022-10-17T04:17:24Z | - |
dc.date.available | 2022-10-17T04:17:24Z | - |
dc.date.created | 2022-10-12 | - |
dc.date.created | 2022-10-12 | - |
dc.date.created | 2022-10-12 | - |
dc.date.created | 2022-10-12 | - |
dc.date.created | 2022-10-12 | - |
dc.date.created | 2022-10-12 | - |
dc.date.created | 2022-10-12 | - |
dc.date.created | 2022-10-12 | - |
dc.date.created | 2022-10-12 | - |
dc.date.created | 2022-10-12 | - |
dc.date.issued | 2022-08 | - |
dc.identifier.citation | JTO Clinical and Research Reports, Vol.3 No.8, p. 100367 | - |
dc.identifier.issn | 2666-3643 | - |
dc.identifier.uri | https://hdl.handle.net/10371/186194 | - |
dc.description.abstract | © 2022 The AuthorsIntroduction: Alectinib is a preferred first-line treatment option for advanced ALK-positive NSCLC. Combination regimens of alectinib with immune checkpoint inhibitors are being evaluated for synergistic effects. Methods: Adults with treatment-naive, stage IIIB/IV, or recurrent ALK-positive NSCLC were enrolled into a two-stage phase 1b study. Patients received alectinib 600 mg (twice daily during cycle 1 and throughout each 21-d cycle thereafter) plus atezolizumab 1200 mg (d8 of cycle 1 and then d1 of each 21-d cycle). Primary objectives were to evaluate safety and tolerability of alectinib plus atezolizumab. Secondary objectives included assessments of antitumor activity. Results: In total, 21 patients received more than or equal to 1 dose of alectinib or atezolizumab. As no dose-limiting toxicities were observed in stage 1 (n = 7), the starting dose and schedule were continued into stage 2 (n = 14). Median duration of follow-up was 29 months (range: 1–39). Grade 3 treatment-related adverse events occurred in 57% of the patients, most often rash (19%). No grade 4 or 5 treatment-related adverse events were reported. Confirmed objective response rate was 86% (18 of 21; 95% confidence interval [CI]: 64–97). Median progression-free survival was not estimable (NE) (95% CI: 13 mo–NE), neither was median overall survival (95% CI: 33 mo–NE). Conclusions: The combination of alectinib and atezolizumab is feasible, but increased toxicity was found compared with the individual agents. With small sample sizes and relatively short follow-up, definitive conclusions regarding antitumor activity cannot be made. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier | - |
dc.title | Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jtocrr.2022.100367 | - |
dc.citation.journaltitle | JTO Clinical and Research Reports | - |
dc.identifier.wosid | 001137481600011 | - |
dc.identifier.scopusid | 2-s2.0-85134565430 | - |
dc.citation.number | 8 | - |
dc.citation.startpage | 100367 | - |
dc.citation.volume | 3 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | CRIZOTINIB | - |
dc.subject.keywordAuthor | Alectinib | - |
dc.subject.keywordAuthor | ALK-positive | - |
dc.subject.keywordAuthor | Atezolizumab | - |
dc.subject.keywordAuthor | Non–small cell lung cancer | - |
dc.subject.keywordAuthor | Phase 1b study | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.